What makes a triple reuptake inhibitor different from standard ADHD meds?
Standard ADHD stimulants (like methylphenidate and amphetamines) primarily boost norepinephrine and dopamine in the brain. Non-stimulants like atomoxetine also target norepinephrine. A serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) adds serotonin to that mix, potentially offering a broader effect on mood, anxiety, and impulse control—common ADHD comorbidities [5][7]. Centanafadine is the leading example in development, and it's described as a 'potential first-in-class' NDSRI (norepinephrine/dopamine/serotonin reuptake inhibitor) [1][2].
The serotonin piece is not just theoretical. A preclinical study of viloxazine, another non-stimulant ADHD drug, showed that it increases cortical serotonin without directly blocking the serotonin transporter—suggesting that serotonin modulation can happen through indirect mechanisms and may contribute to therapeutic effects [6]. While that study is in rats, it supports the idea that adding serotonin to the ADHD treatment equation could be clinically meaningful.
Does it actually work? Yes—and it works across the board.
In two phase 3 trials, centanafadine significantly reduced ADHD symptoms versus placebo in adults. Across 859 patients, both the 200 mg and 400 mg daily doses produced significant improvements on the Adult ADHD Investigator Symptom Rating Scale (AISRS) by day 42 [1][2]. The effect was consistent regardless of whether patients had previously tried stimulants or non-stimulants, and even in the small group who had failed two prior treatments, the 400 mg dose showed significant benefit from day 14 onward [1].
It also worked across severity levels. In the same trials, patients with both low and high baseline symptom severity (split at a median AISRS score of 38) showed significant improvement versus placebo, with benefits appearing as early as day 7 in some groups [2]. Long-term data from a 52-week open-label study showed sustained improvement: average AISRS scores dropped by about 20 points from baseline, and the drug was generally well tolerated [4].
What's the catch? Safety and tolerability look manageable, but watch for side effects.
A thorough QT study—designed to detect heart rhythm risks—found that centanafadine at a supratherapeutic dose (800 mg) had no clinically meaningful effect on cardiac repolarization. The predicted change in QTcF (a heart rhythm measure) was -2.72 milliseconds, well below the 10 ms threshold of concern [3]. This is reassuring because some psychiatric drugs carry QT risks.
Common side effects in the long-term study included insomnia (8.0%), nausea (7.7%), and headache (7.0%) [4]. About 12% of patients discontinued due to adverse events, and 4.7% reported abuse-potential-related events—lower than typical stimulants but not zero [4]. No deaths occurred, and there were no concerning trends in lab values or vital signs [4].
About These Sources
This answer is built on 7 peer-reviewed studies — published from 2023 to 2026, 6 from 2024 or later, 6 in Q1 journals — selected as the most relevant from 9 studies that passed quality screening, drawn from 78 papers retrieved from a database of over 500 million.
Sources used in this answer
Centanafadine Sustained Release Is Efficacious in Patients with Adult ADHD, Regardless of Their Treatment History
In a pooled analysis of two phase 3 trials (859 adults), centanafadine SR significantly improved ADHD symptoms versus placebo regardless of prior stimulant/non-stimulant treatment history, including in patients who had failed two prior treatments (400 mg dose, P=0.030 at day 42).
Centanafadine Sustained Release Is Efficacious in the Treatment of Adult ADHD Across Disease Severities
In the same phase 3 trials, centanafadine SR was efficacious in adults with both low and high baseline ADHD severity, with significant improvements versus placebo starting as early as day 7 in some groups.
A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization
A thorough QT study in 30 healthy adults found that centanafadine at a supratherapeutic dose (800 mg) had no clinically meaningful effect on cardiac repolarization; the predicted QTcF change was -2.72 ms, and no participant had a QTcF increase >30 ms.
52-Week Open-Label Safety and Tolerability Trial of Centanafadine Sustained Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
In a 52-week open-label trial (653 adults), centanafadine SR 400 mg/day was safe and effective long-term, with mean AISRS scores improving by about 20 points; common side effects were insomnia, nausea, and headache.
Connecting the dots and finding the way forward: Pharmacological, neuromodulatory, and psychotherapeutic interventions for the complex treatment of adult ADHD
A review highlights that stimulants remain first-line for adult ADHD due to superior efficacy, but notes that novel agents like centanafadine (triple reuptake inhibitor) and solriamfetol show promising phase III results, and emphasizes the need for multimodal, personalized treatment approaches.
Viloxazine Increases Cortical Serotonin Without Inhibiting Serotonin Reuptake at Doses Used to Treat ADHD
A preclinical microdialysis study in rats showed that viloxazine, a non-stimulant ADHD drug, increases cortical serotonin at clinically relevant doses without inhibiting the serotonin transporter, suggesting an indirect mechanism for serotonin elevation.
The Latest Pathological Mechanisms and Targeted Drugs Research of Attention Deficit Hyperactivity Disorder
A review of ADHD pathology and treatments discusses emerging mechanisms like the immune-metabolic-circuit model and highlights centanafadine as a triple reuptake inhibitor in development, while noting limitations in current research on long-term efficacy and individualized treatment.